Emergent Biosolutions
EBS
181 hedge funds and large institutions have $1.2B invested in Emergent Biosolutions in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 78 increasing their positions, 56 reducing their positions, and 16 closing their positions.
39% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 56
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
16% more capital invested
Capital invested by funds: $1.03B → $1.2B (+$166M)
3% more funds holding
Funds holding: 176 → 181 (+5)
0.5% less ownership
Funds ownership: 87.44% → 86.95% (-0.5%)
64% less call options, than puts
Call options by funds: $1.94M | Put options by funds: $5.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$19.5M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$8.98M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.69M |
| 4 |
BlackRock
New York
|
+$4.65M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$8.43M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.81M |
| 3 |
Millennium Management
New York
|
-$5.47M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$5.47M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.04M |
EBS Hedge Fund Activity: Q2 2017 in Review
181 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2017, worth a combined $1.2B — up 16% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new EBS positions and 16 closed out — a net gain of 6 holders — while 78 added to existing stakes and 56 trimmed.
The largest buyer was Invesco, adding an estimated $19.5M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $8.43M sold.
- 181 institutional investors held Emergent Biosolutions (EBS) as of Q2 2017, up from 176 in Q1 2017.
- Funds reported $1.2B of Emergent Biosolutions stock for Q2 2017, up 16% quarter-over-quarter.
- 22 funds opened new Emergent Biosolutions positions in Q2 2017 and 16 closed out, a net change of +6 holders.
- The largest Emergent Biosolutions buyer in Q2 2017 was Invesco, an estimated $19.5M added.
- The largest Emergent Biosolutions seller in Q2 2017 was Arrowstreet Capital, an estimated $8.43M sold.
Based on aggregated 13F filings for Q2 2017.